- Report: Specialty pharmacy to account for half of all prescription revenue by 2018
- Drug Channels: Express Scripts, CVS Caremark and Walgreens top players in specialty pharmacy
- Walgreens firing on all cylinders as chain realizes a total comp sales increase of 5.4% for its first quarter
- Reports: ESI may start 'price war' over new hepatitis C drugs
- 21 health industry groups address FDA on proposed changes to generic drug label rules
ST. LOUIS — Pharmacy benefit manager Express Scripts reported its third-quarter results for the period ended Sept. 30.
ESI said that its revenue grew from about $11.3 billion in the third quarter 2010 to nearly $11.6 billion. The company also reported that adjusted earnings per diluted share was 79 cents, representing a 22% increase over last year. Additionally, net income from continuing operations were $324.7 million, compared with $301.5 million in the year-ago period.
In line with the release of its third-quarter results, the company reaffirmed its 2011 guidance, noting that it expects 2011 adjusted earnings per share in a range of $2.95 to $3.05. ESI said it would provide 2012 guidance after the closing of its transaction with fellow PBM Medco.
“Our third-quarter results reflect the continued execution of our business model and the value of fully aligning with clients,” ESI chairman and CEO George Paz said. “We continue to invest robustly for the future, maintaining our focus on innovation, service and achieving optimal health outcomes. We are confident that these investments will create value for plan sponsors and patients and will continue to drive growth in shareholder value.”